^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TQB2868

    i
    Other names: TQB2868
    Associations

    News

    Trials
    Company:
    Sino Biopharm
    Drug class:
    PD1 inhibitor, TGFβ inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • TQB2868
    6ms
    A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=39 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • TQB2868
    9ms
    A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    New P2 trial • IO biomarker • Metastases
    |
    CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • TQB2868
    2years
    Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=280, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Jan 2022 --> Apr 2022
    Enrollment open • Trial initiation date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    TQB2868
    over2years
    Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
    P1, N=280, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
    New P1 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    PD-L1 expression
    |
    TQB2868